Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BVXV Stock Summary
In the News
BiondVax to Present at BIO-Europe Spring
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
BiondVax Presenting at BIO CEO & Investor Conference
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.
BiondVax to Present at LD Micro Investor Conference in Los Angeles
Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.
BiondVax to present at LD Micro Investor Conference in Los Angeles
JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.
BiondVax to Present at this week's Biomed Israel Conference
JERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
BVXV Financial details
BVXV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 1.95 | 0 | |
Net income per share | -35.64 | -151.98 | 6.15 | -36 | 0 | |
Operating cash flow per share | -87.51 | -94.36 | -65.46 | -17.35 | 0 | |
Free cash flow per share | -123.82 | -103.46 | -70.99 | -17.65 | 0 | |
Cash per share | 30.83 | 88.74 | 2.64 | 38.28 | 0 | |
Book value per share | -12.68 | -79.66 | -4.1 | 16.53 | 0 | |
Tangible book value per share | -12.68 | -79.66 | -4.1 | 16.53 | 0 | |
Share holders equity per share | -12.68 | -79.66 | -4.1 | 16.53 | 0 | |
Interest debt per share | 43.86 | 179.03 | 23.24 | 57.08 | 0 | |
Market cap | 116.29M | 261.79M | 100.06M | 102.96M | 2232.07B | |
Enterprise value | 121.2M | 320.61M | 118.02M | 118.66M | 2232.07B | |
P/E ratio | -4.99 | -2.11 | 14.68 | -2.03 | -4.2M | |
Price to sales ratio | 0 | 0 | 0 | 37.47 | 0 | |
POCF ratio | -2.03 | -3.4 | -1.38 | -4.21 | -307.24K | |
PFCF ratio | -1.44 | -3.1 | -1.27 | -4.13 | -275.53K | |
P/B Ratio | -14.03 | -4.02 | -22.04 | 4.41 | -1.27M | |
PTB ratio | -14.03 | -4.02 | -22.04 | 4.41 | -1.27M | |
EV to sales | 0 | 0 | 0 | 43.18 | 0 | |
Enterprise value over EBITDA | -6.16 | -4.17 | 33.95 | -3.66 | -212.6K | |
EV to operating cash flow | -2.12 | -4.16 | -1.63 | -4.85 | -307.24K | |
EV to free cash flow | -1.5 | -3.79 | -1.5 | -4.76 | -275.53K | |
Earnings yield | -0.2 | -0.47 | 0.07 | -0.49 | 0 | |
Free cash flow yield | -0.7 | -0.32 | -0.79 | -0.24 | 0 | |
Debt to equity | -3.02 | -2.02 | -4.6 | 2.99 | -12.24 | |
Debt to assets | 0.89 | 1.13 | 1.18 | 0.7 | 0.8 | |
Net debt to EBITDA | -0.25 | -0.77 | 5.17 | -0.48 | -0.71 | |
Current ratio | 3.53 | 3.86 | 0.17 | 7.64 | 6.15 | |
Interest coverage | -5.67 | -5.25 | 0.21 | -3.22 | 2.1 | |
Income quality | 0.65 | 0.71 | 16.28 | 0.61 | 1.25 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 8.73 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 3.76 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.41 | 0.1 | 0.08 | 0.02 | 0.12 | |
Capex to revenue | 0 | 0 | 0 | -0.16 | 0 | |
Capex to depreciation | -91.27 | -4.52 | -2.52 | -0.18 | -1.49 | |
Stock based compensation to revenue | 0 | 0 | 0 | 3.24 | 0 | |
Graham number | 100.85 | 521.92 | 23.81 | 115.71 | 0 | |
ROIC | -1.37 | -1.21 | -0.28 | -0.44 | -0.05 | |
Return on tangible assets | -0.83 | -1.07 | 0.39 | -0.51 | -0.02 | |
Graham Net | -25 | -132.34 | -17.17 | -15.59 | 0 | |
Working capital | 14.62M | 54.16M | -16.66M | 47.84M | 12.03M | |
Tangible asset value | -8.29M | -65.05M | -4.54M | 23.33M | -1.76M | |
Net current asset value | -15.99M | -107.68M | -18.93M | -21.22M | -14.46M | |
Invested capital | -3.02 | -2.02 | -4.6 | 2.99 | -12.24 | |
Average receivables | 1.71M | 302.61K | 361.72K | 340.22K | 208K | |
Average payables | 5.86M | 11.28M | 8.82M | 1.84M | 1.91M | |
Average inventory | -291K | -291K | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 40.64 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 8.98 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 2.81 | 1.91 | -1.5 | -2.18 | 0.3 | |
Capex per share | -36.31 | -9.1 | -5.53 | -0.3 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.62 | 0 | |
Net income per share | -6.47 | 5.24 | 0 | -1.19 | -1.11 | |
Operating cash flow per share | -5.57 | 0 | 0 | -0.94 | -0.85 | |
Free cash flow per share | -5.6 | 0 | 0 | -0.95 | -0.96 | |
Cash per share | 21.15 | 15.76 | 0 | 3.33 | 2.22 | |
Book value per share | 2.39 | 5.01 | 0 | -1.49 | -2.1 | |
Tangible book value per share | 2.39 | 5.01 | 0 | -1.49 | -2.1 | |
Share holders equity per share | 2.39 | 5.01 | 0 | -1.49 | -2.1 | |
Interest debt per share | 43.22 | 36.5 | 0 | 7.29 | 7.28 | |
Market cap | 76.65M | 48.58M | 2232.07B | 6.99M | 4.77M | |
Enterprise value | 114.21M | 81.16M | 2232.07B | 19.47M | 21.87M | |
P/E ratio | -1.59 | 1.24 | 99.7K | -0.45 | -0.32 | |
Price to sales ratio | 0 | 0 | 0 | 3.47 | 0 | |
POCF ratio | -7.37 | 0 | 140.82K | -2.29 | -1.66 | |
PFCF ratio | -7.34 | 0 | 145.31K | -2.28 | -1.46 | |
P/B Ratio | 17.16 | 5.19 | -1.27M | -1.45 | -0.67 | |
PTB ratio | 17.16 | 5.19 | -1.27M | -1.45 | -0.67 | |
EV to sales | 0 | 0 | 0 | 9.66 | 0 | |
Enterprise value over EBITDA | -13.54 | 8.19 | -240.69K | -6.39 | -8.43 | |
EV to operating cash flow | -10.98 | 0 | 140.82K | -6.37 | -7.61 | |
EV to free cash flow | -10.93 | 0 | 145.31K | -6.35 | -6.72 | |
Earnings yield | -0.16 | 0.2 | 0 | -0.55 | -0.79 | |
Free cash flow yield | -0.14 | 0 | 0 | -0.44 | -0.68 | |
Debt to equity | 17.25 | 6.63 | -12.24 | -4.84 | -3.46 | |
Debt to assets | 0.9 | 0.83 | 0.8 | 1 | 1.24 | |
Net debt to EBITDA | -4.45 | 3.29 | -0.81 | -4.09 | -6.59 | |
Current ratio | 1.71 | 5.75 | 6.15 | 4.28 | 4.12 | |
Interest coverage | -2.96 | 0.63 | 1.1 | -9.68 | 0 | |
Income quality | 0.81 | 0 | 0.59 | 0.87 | 0.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0.99 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | -0.03 | 0 | 0.13 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.06 | 0 | 0.34 | -0.04 | -2.56 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.13 | 0 | |
Graham number | 18.66 | 24.31 | 0 | 6.3 | 7.26 | |
ROIC | -0.12 | 0.13 | 2.99 | -0.18 | -0.13 | |
Return on tangible assets | -0.14 | 0.13 | 0.21 | -0.17 | -0.19 | |
Graham Net | -22.03 | -18.94 | 0 | -5.32 | -5.74 | |
Working capital | 16.61M | 24.91M | 12.03M | 8.47M | 5.88M | |
Tangible asset value | 4.47M | 9.36M | -1.76M | -4.81M | -7.11M | |
Net current asset value | -40.98M | -35.2M | -14.46M | -17.06M | -19.24M | |
Invested capital | 17.25 | 6.63 | -12.24 | -4.84 | -3.46 | |
Average receivables | 622.5K | 669.5K | 411.5K | 114.5K | 128.5K | |
Average payables | 3.08M | 1.56M | 885K | 1.01M | 982K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 5.31 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 16.94 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -2.7 | 1.05 | -3.18 | 0.8 | 0.53 | |
Capex per share | -0.02 | 0 | 0 | 0 | -0.11 |
BVXV Frequently Asked Questions
What is BiondVax Pharmaceuticals Ltd. stock symbol ?
BiondVax Pharmaceuticals Ltd. is a IL stock and trading under the symbol BVXV
What is BiondVax Pharmaceuticals Ltd. stock quote today ?
BiondVax Pharmaceuticals Ltd. stock price is $1.36 today.
Is BiondVax Pharmaceuticals Ltd. stock public?
Yes, BiondVax Pharmaceuticals Ltd. is a publicly traded company.